8-K: Black Diamond Therapeutics Announces Promising Phase 2 Data for BDTX-1535 in Lung Cancer

Black Diamond Therapeutics reports encouraging initial Phase 2 results for BDTX-1535, showing robust anti-tumor activity in patients with recurrent EGFR-mutant non-small cell lung cancer.

Summary

• Black Diamond Therapeutics has released initial Phase 2 data for BDTX-1535, a drug targeting EGFR mutations in non-small cell lung cancer.
• The trial included patients with non-classical EGFR mutations and those with C797S resistance mutations.
• The 200 mg daily dose of BDTX-1535 was selected for pivotal clinical development based on safety, tolerability, and pharmacokinetics.
• The preliminary objective response rate (ORR) was 42% in 19 patients and 36% in 22 response-evaluable patients.
• Of the 19 patients with osimertinib resistance mutations, 8 achieved a response, including 5 confirmed partial responses and 3 unconfirmed partial responses.
• The duration of response was approximately 8 months or more for the first three patients with a partial response.
• The most common adverse events were rash (70%) and diarrhea (35%), mostly mild or moderate.
• The company expects to share initial results from the first-line cohort and outline potential registration paths in Q1 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical data with a good response rate and tolerability profile, suggesting a promising outlook for the drug's development. The management's comments are also optimistic, contributing to a positive sentiment.

Positives

• BDTX-1535 demonstrated a 42% objective response rate in a subset of patients with on-target resistance EGFR mutations.
• The drug showed encouraging durability, with some patients experiencing a response lasting 8 months or more.
• The tolerability profile of BDTX-1535 at 200 mg was favorable, with mostly mild to moderate adverse events.
• The 200 mg dose was selected for pivotal development, indicating confidence in its efficacy and safety.
• The drug is being tested in both recurrent and first-line settings, potentially expanding its application.

Negatives

• The most common adverse events were rash (70%) and diarrhea (35%), although mostly mild or moderate.
• There were two cases of grade 3 rash, although no grade 4 rash or grade 3/4 diarrhea were reported.

Risks

• The results are preliminary and based on a limited number of patients.
• The actual results may differ from the forward-looking statements due to various risks and uncertainties.
• The company is still in the process of seeking regulatory feedback and determining the registration path.
• The success of the drug in the first-line setting is not yet confirmed.

Future Outlook

The company anticipates regulatory feedback on the registration path for BDTX-1535 in Q1 2025 and expects to share initial results from the first-line cohort in the same timeframe. They also plan to continue enrolling patients in secondand third-line cohorts.

Management Comments

• Sergey Yurasov, M.D., Chief Medical Officer, stated that the preliminary Phase 2 data demonstrates the potential of BDTX-1535 to deliver durable responses for patients with on-target resistance EGFR mutations.
• Danny Nguyen, M.D., Assistant Clinical Professor, noted that the initial Phase 2 data with BDTX-1535 looks quite promising for patients who progress on osimertinib.
• Mark Velleca, M.D., Ph.D., Chief Executive Officer, expressed pleasure with the Phase 2 clinical activity and tolerability, and believes the activity observed in the recurrent setting can translate to robust clinical benefit in the first-line setting.

Industry Context

This announcement is significant in the context of the ongoing need for effective treatments for EGFR-mutant NSCLC, particularly for patients who have developed resistance to existing therapies like osimertinib. The development of a fourth-generation TKI like BDTX-1535 addresses a critical unmet need in this patient population.

Comparison to Industry Standards

• The reported 42% ORR in patients with on-target resistance mutations is competitive with other experimental therapies in this space, such as some third-generation TKIs and antibody-drug conjugates.
• The 8-month duration of response is also encouraging, as many therapies in this setting struggle to provide long-lasting benefits.
• The tolerability profile appears favorable compared to chemotherapy, which is often the next line of treatment after TKI resistance.
• Companies like AstraZeneca (Tagrisso/Osimertinib) and Takeda (Exkivity/Mobocertinib) are key competitors in the EGFR-mutant NSCLC space, and BDTX-1535 is aiming to address the resistance mechanisms that limit the effectiveness of these drugs.

Stakeholder Impact

• Shareholders may react positively to the encouraging clinical data.
• Patients with EGFR-mutant NSCLC may benefit from a new treatment option.
• Employees of Black Diamond Therapeutics may be motivated by the positive results.
• The company's reputation may improve due to the positive clinical trial results.

Next Steps

• The company will continue to enroll patients in the secondand third-line cohorts, as well as in the first-line setting for patients with non-classical EGFR mutations.
• The company expects to disclose initial results from the first-line cohort in Q1 2025.
• The company expects to outline potential registrational paths in the recurrent setting based on FDA feedback in Q1 2025.

Key Dates

Keywords

BDTX-1535, EGFR, NSCLC, Lung Cancer, Oncology, Phase 2 Trial, Tyrosine Kinase Inhibitor, Osimertinib Resistance, Clinical Trial, Drug Development